CDK4/6 inhibitors: a novel strategy for tumor radiosensitization

Recently, the focus of enhancing tumor radiosensitivity has shifted from chemotherapeutics to targeted therapies. Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are a novel class of selective cell cycle therapeutics that target the cyclin D-CDK4/6 complex and induce G1 phase arrest. These agent...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yilan, Luo, Jurui, Chen, Xingxing, Yang, Zhaozhi, Mei, Xin, Ma, Jinli, Zhang, Zhen, Guo, Xiaomao, Yu, Xiaoli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490904/
https://www.ncbi.nlm.nih.gov/pubmed/32933570
http://dx.doi.org/10.1186/s13046-020-01693-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490904/
https://www.ncbi.nlm.nih.gov/pubmed/32933570
http://dx.doi.org/10.1186/s13046-020-01693-w

Ejemplares similares